Company Description
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States.
Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease.
The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
| Country | United States |
| Founded | 1996 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | J. Finley |
Contact Details
Address: 4600 South Syracuse Street, Suite 900 Denver, Colorado 80237 United States | |
| Phone | 858 704 4900 |
| Website | palisadebio.com |
Stock Details
| Ticker Symbol | PALI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001357459 |
| CUSIP Number | 696389105 |
| ISIN Number | US6963894026 |
| Employer ID | 52-2007292 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| J. D. Finley | Chief Executive Officer, Chief Financial Officer and Director |
| Dr. Mitchell Lawrence Jones M.D., Ph.D. | President and Chief Medical Officer |
| Ramesh C. Donthamsetty | Head of Corporate Development and Investor Relations |
| Dr. Joerg Heyer Ph.D. | Head of Translational Science and Medicine |
| Sharon Skare Ph.D. | Vice President and Global Head of Clinical Operations |
| Dr. James Izanec M.D. | Vice President and Head of Clinical Development |
| Daniel J. Larkins | Head of Global Regulatory Affairs |
| Adarsh Patel M.B.A., M.S. | Head of Chemistry, Manufacturing and Controls |
| Ryker Willie | Senior Vice President of Finance and Corporate Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 17, 2026 | PRE 14A | Other preliminary proxy statements |
| Apr 2, 2026 | 8-K | Current Report |
| Mar 20, 2026 | 10-K | Annual Report |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 13, 2026 | SCHEDULE 13G/A | Filing |
| Feb 10, 2026 | SCHEDULE 13G | Filing |
| Jan 29, 2026 | SCHEDULE 13G | Filing |